Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/28/25 Merck & Co (MRK) Welireg for Renal Cell Cancer (RCC) Subscribers Only Subscribers Only Subscribers Only
10/28/25 Eisai (4523) Lenvima for Renal Cell Cancer (RCC) Subscribers Only Subscribers Only Subscribers Only
10/27/25 Hanmi Pharmaceutical (A008930) efpeglenatide for Obesity Subscribers Only Subscribers Only Subscribers Only
10/22/25 Ventyx Biosciences (VTYX) VTX-3232 for Obesity Subscribers Only Subscribers Only Subscribers Only
10/21/25 Terns Pharmaceuticals (TERN) TERN-601 for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update